The prevalence of anti-HCV positivity in patients undergoing haemodialysis or with malignant disease

Basit Öğe Kaydı
dc.authorid0000-0002-8335-1927en_US
dc.contributor.authorPaydaş, Semra
dc.contributor.authorAksu, Hasan Zeki
dc.contributor.authorPaydaş, Semra
dc.contributor.authorBurgut, Hüseyin Refik
dc.contributor.authorSağlıker, Yahya
dc.date.accessioned2024-07-12T21:11:19Z
dc.date.available2024-07-12T21:11:19Z
dc.date.issued1994en_US
dc.departmentFakülteler, Tıp Fakültesien_US
dc.description.abstractWe studied the occurrence of anti-hepatitis C (HCV) antibodies in patients with malignant disease (53), in patients undergoing haemodialysis (56), and in blood donors (204) as healthy population controls. The study was carried out using the second-generation EIA test. Anti-HCV positivity was 23.2% in haemodialysis (HD) patients, 0.5% in blood donors, and 0% of the patients with malignant disease (MD). There was no association between anti-HCV positivity and the results of AST, ALT and HBsAg tests in patients and controls. But there was significant association of blood transfusion frequency and duration of HD with anti-HCV positivity in patients undergoing HD, and conversely an absence of this association in patients with MD. However, two of the anti-HCV-positive HD patients did not have any blood transfusion history. One HCV-positive blood donor had a history of surgical operation. Nosocomial transmission of HCV infection has replaced blood transfusion as the main risk factor in HD patients, and preventive measures should be performed in this direction to control infection.en_US
dc.identifier.citationPaydaş, S., Aksu, H. S., Burgut, H. R. ve Sağlıker, Y. (1994). The prevalence of anti-HCV positivity in patients undergoing haemodialysis or with malignant disease. The British Journal of Clinical Practice. 48(1), s. 25-26.en_US
dc.identifier.endpage26en_US
dc.identifier.issn0007-0947
dc.identifier.issue1en_US
dc.identifier.startpage25en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/4360
dc.identifier.volume48en_US
dc.institutionauthorBurgut, Hüseyin Refik
dc.language.isoenen_US
dc.publisherNational Center for Biotechnology Informationen_US
dc.relation.ispartofThe British Journal of Clinical Practiceen_US
dc.relation.publicationcategoryUluslararası Hakemli Dergide Makale - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY03508
dc.titleThe prevalence of anti-HCV positivity in patients undergoing haemodialysis or with malignant diseaseen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

Tıp Fakültesi Koleksiyonu